Search

Your search keyword '"Vinel, J. P."' showing total 225 results
Start Over Author "Vinel, J. P."
225 results on '"Vinel, J. P."'

2. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E

Author

Perrin, H. Blasco, Cintas, P., Abravanel, F., Gerolami, R., d'Alteroche, L., Raynal, J.-N., Alric, L., Dupuis, E., Prudhomme, L., Vaucher, E., Couzigou, P., Liversain, J.-M., Bureau, C., Vinel, J.-P., Kamar, N., Izopet, J., and Peron, J.-M.

Subjects
American Medical Association, Care and treatment, Development and progression, Health aspects, Hepatitis E -- Development and progression -- Care and treatment -- Health aspects, Infection -- Development and progression -- Care and treatment -- Health aspects, Miller Fisher syndrome -- Development and progression -- Care and treatment -- Health aspects, Nervous system diseases -- Development and progression -- Care and treatment -- Health aspects
Abstract

Hepatitis E virus (HEV) infection is an emerging autochthonous disease in industrialized countries (1). Locally acquired (autochthonous) HEV 3 or HEV 4 infections are believed to be a porcine zoonosis. [...]

Published
2015
Full Text
View/download PDF

6. TIPS

Author

Otal, Ph., primary, Bureau, C., additional, Lagarde, S., additional, Mokrane, T., additional, Vinel, J.-P., additional, and Rousseau, H., additional

Published
2013
Full Text
View/download PDF

19. DIAGNOSIS AND MANAGEMENT OF HAEMOCHROMATOSIS SINCE THE DISCOVERY OF THE HFE GENE: A EUROPEAN EXPERIENCE

Author

Robson, K. J. H., Merryweather-Clarke, A. T., Pointon, J. J., Shearman, J. D., Halsall, D. J., Kelly, A., T. M., Rosenberg, W. M., Howell, M., Eccles, D., Patch, C., Fowler, A. V., Wallace, D. F., Camaschella, C., Roetto, A., Zecchina, G., De Gobbi, M., Gasparini, P., Cadet, E., Vandwalle, J. L., Capron, D., Rochette, J., Borot, N., Demangel, C., Dery, R., Vinel, J. P., Pascal, J. P., Coppin, H., and Roth, M.-P.

Published
2000

22. P587 PROGNOSTIC VALUE OF AFP LEVELS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: PROSPECTIVE EVALUATION OF 715 CONSECUTIVE PATIENTS PRESENTED AT OUR MULTIDISCIPLINARY COMMITTEE FROM 2006 TO 2011

Author

Fourquet-Offredi, E., primary, Berard, E., additional, Christol, C., additional, Muscari, F., additional, Otal, P., additional, Bureau, C., additional, Buscail, L., additional, Faruch, M., additional, Robic, M.-A., additional, Vinel, J.-P., additional, and Peron, J.-M., additional

Published
2014
Full Text
View/download PDF

23. Diagnosis and management of haemochromatosis since the discovery of the HFE gene: a european experience

Author

The, European, UK Haemochromatosis Consortia, represented by: Robson, K. J. H., Merryweather Clarke, A. T., Pointon, J. J., Shearman, J. D., Halsall, D. J., Kelly, A., Cox, T. M., Rosenberg, W. M., Howell, M., Eccles, D., Patch, C., Fowler, A. V., Wallace, D. F., Camaschella, C., Roetto, Antonella, Zecchina, G., DE GOBBI, Marco, Gasparini, P., Cadet, E., Vandwalle, J. L., Capron, D., Rochette, J., Borot, N., Demangel, C., Dery, R., Vinel, J. P., Pascal, J. P., Coppin, H., and Roth, M. P.

Published
2000

26. 564 TREATMENT OF AUTOCHTHONOUS ACUTE HEPATITIS E IN IMMUNOCOMPETENT PATIENTS WITH SHORT TERM RIBAVIRIN: A MULTICENTRIC FRENCH EXPERIENCE

Author

Nana, J., primary, Borentain, P., additional, Anty, R., additional, Abravanel, F., additional, Bureau, C., additional, Robic, M.-A., additional, Alric, L., additional, Colson, P., additional, Izopet, J., additional, Vinel, J.-P., additional, Kamar, N., additional, Gérolami, R., additional, and Peron, J.-M., additional

Published
2012
Full Text
View/download PDF

27. 208 MONOCENTRIC PROSPECTIVE EVALUATION OF CHEMOEMBOLISATION (TACE) FOR HEPATOCELLULAR CARCINOMA (HCC) SINCE THE DEVELOPMENT OF THE AASLD GUIDELINES

Author

Aziz, K., primary, Auriol, J., additional, Bureau, C., additional, Lauwers-Cances, V., additional, Muscari, F., additional, Carrere, N., additional, Pey, F., additional, Canevet, G., additional, Buscail, L., additional, Vinel, J.-P., additional, Otal, P., additional, and Péron, J.-M., additional

Published
2010
Full Text
View/download PDF

31. Estudio aleatorizado, multicentrico y comparativo entre laparacentesis total con infusion de seroalbumina (PT + ALB) y anastomosis peritoneovenosa (AVP) con punta de titanio en eltratamiento de los pacientes cirroticos con ascitis refractaria

Author

Ginès, A., Planas, R., Angeli, Paolo, Guarner, C., Salerno, F., Vargas, V., Bocchia, S., Vinel, J. P., Salo, J. Ginès P., Gassull, M. A., Gatta, Angelo, Rodriguezn, Arroyo, V., and Grupo Interhospitalario Europeo para el Estudio de la Ascitis, Rodés J.

Published
1993

37. Traitement de l'hypertension portale. Recommandations. Club Francophone pour l'Etude de l'Hypertension Portale.

Author

Cales, P., Castaing, Denis, Grangé, J D, Lebrec, Didier, Le Moine, Olivier, Poynard, T, Silvain, C, Sogni, P, Vinel, J P, Vons, C, Nouel, O, Bourgeois, Nadine, Bernard, Benoît, Hadengue, Antoine, Cales, P., Castaing, Denis, Grangé, J D, Lebrec, Didier, Le Moine, Olivier, Poynard, T, Silvain, C, Sogni, P, Vinel, J P, Vons, C, Nouel, O, Bourgeois, Nadine, Bernard, Benoît, and Hadengue, Antoine

Abstract

Journal Article, Review, info:eu-repo/semantics/published

Published
1999

48. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.

Author

J. M. Péron, Bureau, C., Gourdy, P., Lulka, H., Souque, A., Calippe, B., Selves, J., Al Saati, T., Bernad, J., Cordelier, P., Couderc, B., Pradayrol, I., Pipy, B., Buscail, L., and Vinel, J. P.

Subjects
CANCER, PANCREAS, PROGNOSIS, TUMOR growth, INTERLEUKINS, GROWTH factors, ANTINEOPLASTIC agents
Abstract

Background: Peritoneal carcinomatosis from pancreatic cancer has a poor prognosis with a median survival of 3.1 months. This is mainly due to lack of effective treatment. Interleukin 1 2 (IL12) is a proinflammatory cytokine that has a potent antitumoral effect by stimulating innate and adoptive immunity. Aim: To examine the antitumoral effect and toxicity of intraperitoneal delivery of IL12 using an ex vivo gene therapy approach in a murine model of pancreatic peritoneal carcinomatosis. Methods: Peritoneal carcinomatosis was generated by direct intraperitoneal inoculation of the pancreatic cancer cell line Capon-1 in athymic mice. Syngenic fibroblasts were genetically modified in vitro to secrete IL12 using a polycistronic TFG murine IL12 retroviral vector coding for both p35 and p40 murine IL12 subunits. Ex vivo gene therapy involved injection of the genetically modified fibroblasts intraperitoneally twice a week for 4 weeks. Results: Treatment of pre-established peritoneal carcinomatosis with fibroblasts genetically modified to express IL12 induced a marked inhibition of tumour growth as measured by comparison of the weights of the intraperitoneal tumour nodules in the treated and control animals (3.52 (SD 0.47) v 0.93 (SD 0.21) g, p<0.05) and improved survival. This effect was associated with infiltration of the peritoneal tumour nodules with macrophages. Peritoneal lavage confirmed enhancement of the innate peritoneal inflammatory activity, with an increased number of activated macrophages and natural killer cells. Moreover, macrophages harvested from animals with peritoneal carcinomatosis and treated with IL12-expressing fibroblasts expressed an activated proinflammatory antitumoral Ml phenotype that included strongly enhanced reactive oxygen species and nitric oxide production. There was no treatment-related toxicity. Conclusion: Multiple injections of genetically modified fibroblasts to express IL12 is an effective and well- tolerated treatment for experimental murine pancreatic peritoneal corcinomatosis via activated innate immunity and in particular activated Ml macrophages. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

50. Hepatitis C Virus Genotype 5: Epidemiological Characteristics and Sensitivity to Combination Therapy with Interferon-a plus Ribavirin.

Author

Legrand-Abravanel, F., Sandres-Saune, K., Barange, K., Alric, L., Moreau, J., Desmora, P., Vinel, J. P., and Izopet, J.

Subjects
HEPATITIS C virus, EPIDEMIOLOGICAL research, MICROBIAL sensitivity tests, INTERLEUKINS, RIBAVIRIN, GENETICS, PATIENTS
Abstract

Twenty-six patients living in the Midi-Pyrenees region of France who were infected with hepatitis C virus (HCV) genotype 5 were investigated. Most of these patients were of advanced age and had been infected nosocomially or by blood transfusion. Our case-control study, in which we treated patients with interferon-a plus ribavirin, indicated that, 24 weeks after the beginning of treatment, the virus response in patients infected with HCV genotype 5 was better than that in patients infected with HCV genotype 1 (100% of patients negative for detectable HCV RNA vs. 36.3%, respectively; P<.01); furthermore, 48 weeks after the end of treatment, the virus response in patients infected with HCV genotype 5 was better than that in patients infected with HCV genotype 1 (63.6% vs. 22.7%, respectively; P<.05) and was similar to that in patients infected with HCV genotype 2 or 3 (66.6%). These results show that HCV genotype 5 might have good intrinsic sensitivity to combination therapy with interferon-a plus ribavirin. [ABSTRACT FROM AUTHOR]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results